Erasca, Inc.
ERAS
Kedudukan dalam Saham
#3400
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Harga Saham
$14.51
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$5.08B
Perubahan (1 hari)
-0.75%
Perubahan (1 tahun)
539.21%
Negara
US
Perdagangan Erasca, Inc. (ERAS)
Kategori
Healthcare
Sejarah harga saham bagi Erasca, Inc. (ERAS)
Harga penutupan tertinggi: $14.66 pada 2026-10-01
Harga penutupan terendah: $19.40 pada 2021-07-01
Harga penutupan terendah: $19.40 pada 2021-07-01
Sejarah harga saham Erasca, Inc. dari 2021 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 260.18% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
